Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Published in: Haematologica
Access to document 10.3324/haematol.2018.207829 document
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Sven Borchmann, Ilske Oschlies, Antje Schnitter, Andreas Engert, Peter Borchmann, Wolfram Klapper
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Published in: Haematologica
Access to document 10.3324/haematol.2018.196279 document
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Ilske Oschlies, Antje Schnitter, Sven Borchmann, Andreas Engert, Peter Borchmann, Wolfram Klapper
Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant
Francesco d'Amore, Sirpa Leppa, Maria Gomes da Silva, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, Hans Hagberg, P. J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. ChristensenMilada Jankovska, Par L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, Mats A. Merup, Thomas Noesslinger, Eric Van den Neste, Josee M. Zijlstra, Georg Hopfinger, V. I. T. Prochazka, Esa Jantunen, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M. A. Delabie, Laurence de Leval, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundstrom, Lorenz Truemper, Gerald Wulf, Lauren Chong, Alyssa Bouska, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, Markus Loeffler, Knut Liestol, Christian Steidl, Randy D. Gascoyne, David W. Scott, Bettina Altmann, Javeed Iqbal, Wing C. Chan, Helle Toldbod
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Published in: Cancers
Access to document 10.3390/cancers10110459 document
Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally assess the mutational evolution and to identify gene mutations specific for relapse samples from patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A minority of the mutations detected in the primary sample (median...
Marcel Nijland, Annika Seitz, Martijn Terpstra, Gustaaf W van Imhoff, Philip M Kluin, Tom van Meerten, Çiğdem Atayar, Léon C van Kempen, Arjan Diepstra, Klaas Kok, Anke van den Berg
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones
Published in: Cancer cell
Access to document 10.1016/j.ccell.2018.08.014
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To address this problem, we performed label-free quantitative proteomics on primary acute myeloid leukemia (AML) samples. We identified 50 leukemia-enriched plasma membrane proteins enabling the prospective isolation of genetically distinct subclones from individual AML patients. Subclones differed in their regulatory phenotype, drug sensitivity, growth, and engraftment behavior, as determined by RNA sequencing, DNase I hypersensitive site mapping, transcription factor occupancy analysis, in vitro culture, and xenograft transplantation. Finally, we show that these markers can be...
Bauke de Boer, Janine Prick, Maurien G. Pruis, Peter Keane, Maria Rosaria Imperato, Jennifer Jaques, Annet Z. Brouwers-Vos, Shanna M. Hogeling, Carolien M. Woolthuis, Marije T. Nijk, Arjan Diepstra, Sebastian Wandinger, Matthias Versele, Ricardo M. Attar, Peter N. Cockerill, Gerwin Huls, Edo Vellenga, Andre B. Mulder, Constanze Bonifer, Jan Jacob Schuringa